More recently, the passive administration of pAbs has also been tested in COVID-19 patients (222–224, 258–267), also known as convalescent plasma (CP) or immune plasma, which is already used effectively and safely in the treatment of other severe acute respiratory syndrome infections of viral etiology, such as SARS, MERS, and H1N1, and offers only a short-term but rapid immunity to the susceptible individuals (268).